News
RNAC
20.92
-5.85%
-1.30
Weekly Report: what happened at RNAC last week (0930-1004)?
Weekly Report · 3d ago
Cartesian Therapeutics announces employment inducement grant
TipRanks · 5d ago
TAS PARTNERS LLC REPORTS 2.4% STAKE IN CARTESIAN THERAPEUTICS AS OF OCT 2 VS 11.7% AS OF SEPT 25 - SEC FILING
Reuters · 6d ago
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
NASDAQ · 6d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 6d ago
Weekly Report: what happened at RNAC last week (0923-0927)?
Weekly Report · 09/30 10:48
Weekly Report: what happened at RNAC last week (0916-0920)?
Weekly Report · 09/23 10:48
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Seeking Alpha · 09/17 13:45
Weekly Report: what happened at RNAC last week (0909-0913)?
Weekly Report · 09/16 10:40
Buy Rating for Cartesian Therapeutics: Promising Clinical Trials and Innovative mRNA CAR T Cell Therapy
TipRanks · 09/16 06:15
Buy Rating for Cartesian Therapeutics Backed by FDA Designation and Promising Therapy Prospects
TipRanks · 09/13 10:17
Cartesian's Descartes-08 Granted Rare Pediatric Disease Designation By FDA To Treat JDM
NASDAQ · 09/09 11:50
Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment
Dow Jones · 09/09 11:31
CARTESIAN THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR DESCARTES-08 FOR THE TREATMENT OF JUVENILE DERMATOMYOSITIS
Reuters · 09/09 11:00
Weekly Report: what happened at RNAC last week (0902-0906)?
Weekly Report · 09/09 10:48
Cartesian Therapeutics Announces New Employment Inducement Grant
Barchart · 09/06 06:05
Cartesian Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
Dow Jones · 09/04 11:22
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $45 Price Target
Benzinga · 09/04 11:12
Buy Rating on Cartesian Therapeutics: Advancing Cell Therapy with Innovative mRNA-Engineered CAR-T Treatments
TipRanks · 09/04 10:26
Cartesian Therapeutics Has Dosed The First Patient In Its Phase 1 Trial Of Descartes-15, The Company's Next-generation Autologous Anti-B Cell Maturation Antigen mRNA-Engineered Chimeric Antigen Receptor T-cell Therapy
Benzinga · 09/03 11:04
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.